The evidence base is too large to read. Too important to skip.
Evidence explosion
8,000+ immunotherapy papers, doubling every 18 months. No human can read fast enough to stay current.
Biomarker proliferation
PD-L1, TMB, MSI-H, dMMR — which claims survive cross-reference? Which are overfitted to small cohorts?
Trial design pressure
Phase 3 trials cost $50M+. You need evidence synthesis before commitment, not after enrollment.
Evidence synthesis that survives adversarial review.
8,269-paper immunotherapy corpus
Checkpoint inhibitors, CAR-T, combination therapies. PubMed-sourced and indexed by mechanism.
Adversarial claim testing
Independent model families attack your synthesis on mechanism, evidence, and feasibility before a reviewer does.
Citation verification
Every DOI is checked against live databases before delivery. Fabricated or mismatched references are flagged.
What the pipeline produces.
Combination therapy evidence review: PD-1/CTLA-4 combination evidence across a large paper set is checked for contradictions in published response rates and for safety signals that post-hoc analyses under-report, before Phase 2 design.
Research audit for immunotherapy work.
Send one hypothesis, evidence question, or draft section. We run it through the adversarial pipeline and show you what survives.